Durect’s Bupivacaine Granted FDA Orphan Drug Designation

Durect Corp., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration, or FDA, granted orphan drug designation for bupivacaine, the active pharmaceutical ingredient in the investigational transdermal drug patch Eladur.
RTTNews